Sangui Biotech GmbH, of Witten, Germany, said that interim results of preclinical trials testing the hemoglobin-based product SBT102 against septic shock confirmed the statistical significance of interim results the company had communicated in November, when it reported that the candidate was able to improve the oxygen supply of vital organs during the life threatening final phase of sepsis.